Noxopharm reports anti-cancer effects of Veyonda

Sydney anti-cancer treatment company Noxopharm (ASX: NOX) has reported anti-cancer effects of its Veyonda treatment in a small group of patients suffering advanced prostate cancer. The 14 patients’ cancers were metastatic and they had exhausted all treatment options when given Veyonda in association with low-dosage radiation in a single lesion. After six months, cancer progression…

Canberra-esque madness kills the SME-focused innovation patent system

Comment by Peter Roberts Parliament has passed legislation killing the low cost innovation patent system, bowing to arguments from the Productivity Commission. Legislation killing the patent was passed by the Senate last week and followed an essentially economically-focused review that lacked transparency. This is yet another victory in a long list of destructive wins by…